Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT03787680
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Olaparib — DRUG
    300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
  • AZD6738 — DRUG
    160 mg by mouth daily for days 1-7 of a 28-day cycle.

Study Details

The purpose of this study is to test the effectiveness (how well the drugs work), safety, and tolerability of the investigational drug combination of olaparib and AZD6738 for all patients with metastatic castration-resistant prostate cancer.

Key Dates

Start date
Oct 31, 2019
Status verified
Mar 2026
Primary completion
Jan 26, 2023
Completion
Aug 31, 2028

Study Design

Enrollment
49 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1 (DRPro)
    Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair proficient (DRPro).
  • Experimental: Cohort 2 (DRDef)
    Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair deficient (DRDef).

Primary Outcome Measure

Rate of Response (Complete Response [CR] or Partial Response [PR]) in DNA Repair Proficient (DRPro) Patients [ Time Frame: Up to 30 days after study completion (an average of 1 year) ]

Locations (3)

FacilityCityStateZIPSite coordinators
University of Michigan HospitalAnn ArborMichigan48109-
Wayne State University/Karmanos Cancer InstituteDetroitMichigan48201-
University of Virginia Health SystemCharlottesvilleVirginia22908-

Find similar trials in Ann Arbor, MI

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
University of Michigan Hospital· Ann Arbor, MIWayne State University/Karmanos Cancer Institute· Detroit, MIUniversity of Virginia Health System· Charlottesville, VA

Related Studies